Abstract
Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Current Drug Targets
Title: Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
Volume: 10 Issue: 2
Author(s): U. Elsasser-Beile, P. Buhler and P. Wolf
Affiliation:
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Abstract: Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Export Options
About this article
Cite this article as:
Elsasser-Beile U., Buhler P. and Wolf P., Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354601
DOI https://dx.doi.org/10.2174/138945009787354601 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Role of Diet and Nutrition on the Alteration of the Quality and Quantity of Stem Cells in Human Aging and the Diseases of Aging
Current Pharmaceutical Design Silica Nanoparticles as Promising Drug/Gene Delivery Carriers and Fluorescent Nano-Probes: Recent Advances
Current Cancer Drug Targets Lung Cancer: Are we up to the Challenge?
Current Genomics Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Identification of Bioactive Natural Products by Pharmacophore-Based Virtual Screening
Current Pharmaceutical Design Glyoxalase Pathway of Trypanosomatid Parasites: A Promising Chemotherapeutic Target
Current Drug Targets Kisspeptin: A Critical Regulator of Puberty and Reproductive Function
Current Drug Targets miRNA as Regulators of Prostate Carcinogenesis and Endocrine and Chemoresistance
Current Cancer Drug Targets Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Testosterone Action on the Sertoli Cell Membrane: A KIR6.x Channel Related Effect
Current Pharmaceutical Design Outlook on Epigenetic Therapeutic Approaches for Treatment of Gastric Cancer
Current Cancer Drug Targets Non-Melanoma Skin Cancer – Overview
Current Cancer Therapy Reviews Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications
Current Radiopharmaceuticals